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Objectives The aim of this study was to examine the interaction between cigarette smoking and the clinical efficacy of clo-
pidogrel in ST-segment elevation myocardial infarction (STEMI).
Background Cigarette smoking induces cytochrome P450 (CYP)1A2, which converts clopidogrel into its active metabolite, and
prior studies suggest greater inhibition of platelet aggregation by clopidogrel in smokers of 10 cigarettes/day.
Methods The effect of clopidogrel compared with placebo on angiographic and clinical outcomes was examined in 3,429
STEMI patients in the CLARITY–TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocar-
dial Infarction 28) randomized trial stratified by smoking intensity as follows: not current smokers (n  1,732),
and smokers of 1 to 9 (n  206), 10 to 19 (n  354), 20 to 29 (n  715), and 30 cigarettes/day (n  422).
Logistic regression was used to adjust for other baseline characteristics and interaction terms to test for effect
modification.
Results Although clopidogrel reduced the rate of the primary end point of a closed infarct-related artery or death/myo-
cardial infarction before angiography in the CLARITY-TIMI 28 trial, the benefit was especially marked among
those who smoked 10 cigarettes/day (adjusted odds ratio [OR]: 0.49, 95% confidence interval [CI]: 0.37 to
0.66; p  0.0001) compared with those who did not (adjusted OR: 0.72, 95% CI: 0.57 to 0.91; p  0.006; pinter-
action  0.04). Similarly, clopidogrel was significantly more effective at reducing the rate of cardiovascular death,
myocardial infarction, or urgent revascularization through 30 days among those who smoked 10 cigarettes/
day (adjusted OR: 0.54, 95% CI: 0.38 to 0.76; p  0.0004) compared with those who did not (adjusted OR:
0.98; 95% CI: 0.75 to 1.28; p  0.87; pinteraction  0.006).
Conclusions Cigarette smoking seems to positively modify the beneficial effect of clopidogrel on angiographic and clinical
outcomes. This study demonstrates that common clinical factors that influence the metabolism of clopidogrel
might impact its clinical effectiveness. (J Am Coll Cardiol 2009;53:1273–8) © 2009 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.044e
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slopidogrel is an oral thienopyridine inhibitor of the
latelet P2Y12 adenosine diphosphate (ADP) receptor that
as been shown to prevent death and adverse cardiovascular
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008, accepted December 16, 2008.vents in patients with acute coronary syndromes (ACS)
1,2). However, there is substantial interpatient variability in
he response to clopidogrel (3), and several studies have
emonstrated that a diminished response to clopidogrel is
ssociated with an increased risk of ischemic events (4–7).
Clopidogrel is a pro-drug that requires 2-step oxidization
y cytochrome P450 (CYP) enzymes to be transformed into
ts active metabolite, 2-oxoclopidogrel, with CYP1A2 and
YP3A4 being important for the first and second steps,
espectively (8). Genetic and environmental influences on
YP450 enzyme activity are thought to underlie the sub-
tantial interpatient variability in the response to clopidogrel
9–13). Cigarette smoking is a known inducer of CYP1A2
14) and is therefore potentially capable of affecting the
harmacokinetics and pharmacodynamics of clopidogrel.
To that end, a recent study published in the Journal
howed that cigarette smoking was associated with in-
reased platelet inhibition and lower aggregation in re-
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Smoking and Clinical Benefit of Clopidogrel April 14, 2009:1273–8sponse to clopidogrel (15). How-
ever, the clinical significance of
these observations remains unde-
fined. We therefore examined
the interaction between cigarette
smoking and the efficacy of clo-
pidogrel therapy in a randomized
clinical trial of clopidogrel in pa-
tients with an ACS.
Methods
Study population. The design
and primary results of the
CLARITY–TIMI 28 (Clopi-
dogrel as Adjunctive Reperfusion
Therapy–Thrombolysis In Myo-
cardial Infarction 28) trial have
been published (2,16). In brief,
3,491 patients with ST-segment
levation myocardial infarction (STEMI) who presented
ithin 12 h of symptom onset were to receive aspirin, a
brinolytic, and heparin (required if they were to receive a
brin-specific lytic) and were randomized to clopidogrel
300-mg loading dose followed by 75 mg daily) or placebo.
s part of the trial protocol, patients were scheduled to
ndergo coronary angiography 2 to 8 days after initiation of
herapy to assess for late patency of the infarct-related
rtery. Patients were followed for clinical outcomes and
dverse events through 30 days after randomization. Smok-
ng status and number of cigarettes smoked per day at
aseline were collected on the case report form. The protocol
as approved by the relevant institutional review boards, and
ritten informed consent was obtained from all patients.
utcomes. The primary efficacy end point was the com-
osite of Thrombolysis In Myocardial Infarction (TIMI)
ow grade (TFG) 0 or 1 or death or recurrent myocardial
nfarction (MI) before angiography could be performed.
he 30-day clinical end point was a composite of death
rom cardiovascular causes, recurrent MI, or recurrent isch-
mia leading to the need for urgent revascularization.
ngiographic outcomes were assessed by the TIMI Angio-
raphic Core Laboratory, all ischemic events were adjudi-
ated by a Clinical Events Committee, and both were
linded to the assigned treatment arm. Safety end points
ncluded TIMI major and minor bleeding.
tatistical analysis. Patients were stratified into 5 groups
y smoking intensity: noncurrent smokers, and those who
moked 1 to 9, 10 to 19, 20 to 29, and 30 cigarettes/day.
aseline characteristics across groups were compared with
tudent t tests for normally distributed continuous variables,
ilcoxon rank-sum tests for non-normally distributed con-
inuous variables, and chi-square tests for categorical vari-
bles. We also applied, on the basis of published data
xamining the intensity of smoking and the pharmacologic
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
ADP  adenosine
diphosphate
CI  confidence interval
CYP  cytochrome P450
MI  myocardial infarction
OR  odds ratio
STEMI  ST-segment
elevation myocardial
infarction
TFG  Thrombolysis In
Myocardial Infarction flow
grade
TIMI  Thrombolysis In
Myocardial Infarctionesponse to clopidogrel (15), a dichotomous cut point of umoking 10 cigarettes (one-half pack) per day or not. The
dds ratios (ORs) and 95% confidence intervals (CIs) for
he effect of clopidogrel on the outcomes were calculated
ithin each smoking intensity stratum in a logistic regres-
ion model that adjusted for age, sex, region of enrollment
on the basis of the United Nations Statistics Geographic
egion Codes), hypertension, diabetes, infarct location,
ime to fibrinolytic therapy, and type of fibrinolytic. Inter-
ction terms in logistic regression models were used to test
or the statistical significance of effect modification by
moking on the efficacy of clopidogrel (modeled as: smoking
10 cigarettes  randomization to clopidogrel).
esults
total of 3,491 patients underwent randomization in the
LARITY–TIMI 28 trial, and smoking status was avail-
ble for 3,429 patients. A total of 1,732 patients were not
urrent smokers and 1,697 were, the latter consisting of 206
atients who smoked 1 to 9 cigarettes/day, 354 who smoked
0 to 19 cigarettes/day, 715 who smoked 20 to 29 ciga-
ettes/day, and 422 who smoked 30 cigarettes/day. Com-
ared with nonsmokers, smokers were younger, more likely
o be men, less likely to have a history of hypertension or
iabetes, and less likely to present with an anterior MI or get
fibrin-specific fibrinolytic (Table 1).
The effect of clopidogrel on the risk of the primary end
oint of a closed (TIMI flow grade 0 or 1) infarct-related
rtery or death or recurrent MI before angiography could be
erformed stratified by intensity of smoking is shown in
igure 1. Overall, in the trial, clopidogrel reduced the odds
f the primary end point by 36% (OR: 0.64, 95% CI: 0.53
o 0.76, p  0.001). Among nonsmokers or those who
moked less than one-half pack/day, the addition of clopi-
ogrel reduced the rate of the primary end point from 22.3%
o 17.7%, with an adjusted OR of 0.72 (95% CI: 0.57 to
.91; p  0.006). However, among those who smoked
ne-half pack/day or more, the addition of clopidogrel
esulted in a far greater reduction in the rate of the primary
nd point from 20.5% to 11.7%, with an adjusted OR of
.49 (95% CI: 0.37 to 0.66; p  0.0001). A test for
nteraction among smoking, clopidogrel treatment, and the
rimary efficacy end point was significant (p  0.04),
ndicating a significantly greater benefit of clopidogrel in
hose who smoked at least one-half pack/day. Furthermore,
xamining the likelihood of achieving optimal epicardial
ow (TFG 3), treatment with clopidogrel resulted in an
djusted OR of 1.14 (95% CI: 0.94 to 1.39; p  0.18)
mong nonsmokers or those who smoked less than one-half
ack/day versus 1.77 (95% CI: 1.40 to 2.22; p  0.0001)
mong those who smoked one-half pack/day or more
pinteraction  0.007), again demonstrating effect modifica-
ion by smoking on clopidogrel.
The effect of clopidogrel on the risk of cardiovascular
eath, MI, or recurrent ischemia leading to the need for
rgent revascularization by 30 days stratified by intensity of
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April 14, 2009:1273–8 Smoking and Clinical Benefit of Clopidogrelmoking is shown in Figure 2. Overall in the trial, clopi-
ogrel reduced the odds of the 30-day clinical end point by
0% (OR: 0.80, 95% CI: 0.65 to 0.97, p  0.03). We
bserved that the magnitude of treatment benefit with
aseline Characteristics of the Patients
Table 1 Baseline Characteristics of the Patients
Variable
Noncurrent
Smokers
n 1,732
Cigarettes/day, median (IQR) N/A
Age, yrs  SD 61.1 9.6
Male sex, % 77.0
Region, %
North America and Northern and Western Europe 53.2
Southern and Eastern Europe 24.5
Latin America 13.6
Middle East and Australasia 8.7
Hypertension, % 50.8
Hyperlipidemia, % 41.3
Diabetes mellitus, % 20.7
Killip class II to IV, % 7.4
Anterior MI, % 44.7
Time from symptom onset to start of fibrinolytic, h (IQR) 2.7 (1.8–4.2)
Fibrin-specific lytic, % 70.6
Initial heparin, %
Unfractionated heparin 46.2
Low-molecular-weight heparin 30.1
Both 4.8
Neither 18.9
Concurrent administration of a CYP3A4-metabolized statin*, % 60.6
Includes atorvastatin, simvastatin, and lovastatin.
CYP  cytochrome P450; IQR  interquartile range; MI  myocardial infarction.
Primary Endpoint, No./Total (%)
Smoking Status Clopidogrel Placebo        Adj O
Non-smokers 151/864 (17.5) 196/868 (22.6) 0.69 
1-9 cigarettes/day 19/96 (19.8) 22/110 (20.0) 0.95 
10-19 cigarettes/day 20/186 (10.8) 37/168 (22.0) 0.47 
20-29 cigarettes/day 40/356 (11.2) 69/359 (19.2) 0.46 
≥30 cigarettes/day 30/224 (13.4) 43/198 (21.7) 0.56 
Figure 1 Benefit of Clopidogrel on Primary End Point by Smokin
The primary efficacy end point was a composite of Thrombolysis In Myocardial Infa
tion before angiography could be performed. Odds ratios (ORs) are adjusted (Adj) f
and type of fibrinolytic. For each subgroup, the size of the box is proportional to the
fidence intervals (CIs).lopidogrel was associated with the degree of smoking,
nalogous to the angiographic findings. Among nonsmokers
r those who smoked less than one-half pack/day, the
ddition of clopidogrel had no impact on the rate of the
Cigarettes/Day
p Value0–9 10–19 20–29 >30
206 354 715 422
(2–6) 10 (10–15) 20 (20–20) 40 (30–40) N/A
.3 10.5 54.5 10.5 53.1 9.2 52.0 8.3 0.0001
81.1 72.6 83.9 93.6 0.0001
47.1 55.1 46.9 40.3 0.0001
26.7 22.0 29.0 32.7 0.0007
18.4 13.8 13.0 13.0 0.59
7.8 9.0 11.2 14.0 0.0009
45.6 40.9 34.7 33.3 0.0001
34.1 38.3 35.9 35.1 0.04
18.1 9.5 11.9 14.5 0.0001
9.3 7.9 9.8 6.9 0.27
41.3 35.3 36.8 35.8 0.0001
(2.0–4.4) 2.6 (1.6–3.8) 2.7 (1.8–4.2) 2.5 (1.7–3.8) 0.24
68.4 68.4 61.8 70.4 0.0009
45.6 43.2 42.8 50.0 0.16
30.1 30.2 28.1 30.1 0.89
3.9 6.5 5.2 3.8 0.45
20.4 20.1 23.9 16.1 0.016
57.6 58.5 60.6 60.0 0.84
Favors 
Placebo
Favors
Clopidogrel CI)
.88)
.96)
.88)
.72)
.96)
0.1 0.50.25 1.0 2.0 4.0
Adjusted OR (95% CI)
atus
(TIMI) flow grade 0 or 1 on angiography or death or recurrent myocardial infarc-
, sex, region, hypertension, diabetes, infarct location, time to fibrinolytic therapy,
r of individuals included in the analysis. The horizontal lines represent the 95% con-5
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Smoking and Clinical Benefit of Clopidogrel April 14, 2009:1273–80-day clinical end point (13.7% vs. 14.3%), with an
djusted OR of 0.98 (95% CI: 0.75 to 1.28; p  0.87). In
ontrast, among those who smoked one-half pack/day or
ore, the addition of clopidogrel reduced the rate of the
0-day clinical end point from 14.3% to 8.0%, with an
djusted OR of 0.54 (95% CI: 0.38 to 0.76; p  0.0004). A
est for interaction among smoking, clopidogrel treatment,
nd the 30-day clinical end point was significant (p 
.006), indicating a significantly greater benefit of clopi-
ogrel in those who smoked at least one-half pack/day.
imilarly, treatment with clopidogrel significantly reduced
he risk of cardiovascular death or MI among those who
moked one-half pack/day or more (adjusted OR: 0.57, 95%
I: 0.38 to 0.85, p 0.006), whereas it had no effect among
onsmokers or those who smoked less than one-half pack/
ay (adjusted OR: 0.97, 95% CI: 0.71 to 1.32; p  0.84)
pinteraction  0.032).
Rates of TIMI major or minor bleeding were low (2%)
n the entire study. There was no statistically significant
nteraction between smoking and clopidogrel on the risk of
IMI major or minor bleeding (pinteraction  0.90).
iscussion
n a randomized, placebo-controlled trial of clopidogrel in
ver 3,400 patients with STEMI, we found that cigarette
moking, which induces 1 of the key CYP450 enzymes that
ransforms clopidogrel into its active metabolite, was asso-
iated with the magnitude of benefit from clopidogrel on
ngiographic and clinical outcomes. Whereas clopidogrel
ad significant benefit in the entire trial cohort, treatment
Smoking Status Clopidogrel Placebo          Adj O
Non-smokers 119/864 (13.8) 122/868 (14.1) 0.91 (
1-9 cigarettes/day 18/96 (18.8) 12/110 (10.9) 2.07 (
10-19 cigarettes/day 16/186 (8.6) 29/168 (17.3) 0.50 (
20-29 cigarettes/day 30/356 (8.4) 48/359 (13.4) 0.59 (
≥30 cigarettes/day 15/224 (6.7) 27/198 (13.6) 0.46 (
30-Day Clinical Endpoint, No./Total (%)
Figure 2 Benefit of Clopidogrel on 30-Day Clinical End Point by
The 30-day clinical end point was a composite of death from cardiovascular cause
revascularization. ORs are adjusted for age, sex, region, hypertension, diabetes, in
the size of the box is proportional to the number of individuals included in the anaith clopidogrel had approximately twice the efficacy in eeducing both the risk of a closed infarct-related artery or
eath or MI before angiography could be performed and the
isk of cardiovascular death, recurrent MI, or urgent revas-
ularization over 30 days in patients who smoked at least
ne-half pack of cigarettes/day. This study provides another
ossible link in the emerging understanding of clopidogrel
harmacology. In exploring clopidogrel resistance or hypo-
esponsiveness, investigators have now focused on the me-
abolism of clopidogrel to its active metabolite as the key
actor. Building on the recent finding that cigarette smoking
s an inducer of clopidogrel metabolism leading to higher
egrees of platelet inhibition with clopidogrel (15), we now
how that cigarette smoking, in turn, is associated with
ifferences in the clinical effectiveness of clopidogrel.
The emerging recognition that factors influencing the
etabolism of clopidogrel can impact its pharmacologic and
ow clinical efficacy is supported by multiple pharmacologic
bservations. First, CYP1A2 is the predominant enzyme
esponsible for the first oxidative step in the conversion of
lopidogrel to its active metabolite (8). Accelerating the first
tep would help prevent the pro-drug from being shunted
own an esterase-mediated pathway that leads to pharma-
ologically inactive metabolites. Second, cigarette smoke in
eneral and its polycyclic aromatic hydrocarbons in partic-
lar are known to induce CYP1A2 (14). A study comparing
hose who smoked one-half pack/day or more with non-
mokers found a 66% increase in CYP1A2 activity among
mokers (17). Third, among heavy smokers, the half-life for
issipation of CYP1A2 induction upon discontinuation of
moking has been estimated to be 38.6 h, which would
 CI)
.20)
.92)
.99)
.97)
.95)
0.1 0.5
Favors 
Placebo
Favors
Clopidogrel
0.25 1.0 2.0 5.0
Adjusted OR (95% CI)
king Status
rrent myocardial infarction, or recurrent ischemia leading to the need for urgent
ocation, time to fibrinolytic therapy, and type of fibrinolytic. For each subgroup,
The horizontal lines represent the 95% CIs. Abbreviations as in Figure 1.R (95%
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April 14, 2009:1273–8 Smoking and Clinical Benefit of Clopidogrelogrel loading in our study (18). Four, several studies
xamining the association between platelet aggregation and
linical outcomes have noted trends toward a higher pro-
ortion of smokers among patients with less platelet aggre-
ation in response to clopidogrel (4,19,20). Finally, in a
ecent study of smoking and platelet aggregation by Bliden
t al. (15), smokers were noted to have increased platelet
nhibition and lower aggregation in response to clopidogrel
ompared with nonsmokers.
Our results suggest a threshold of smoking at least
ne-half pack/day to significantly impact the efficacy of
lopidogrel. This threshold was also seen in the study by
liden et al. (15). However, given the relatively wide CIs
round the point estimates in those smoking 10 to 19, 20 to
9, and 30 cigarettes/day, we cannot definitely exclude a
ose-response effect within this range. Nonetheless, the
hreshold effect now seen in 2 analyses has important
mplications for interpretation of other studies examining
he presence of an interaction between clopidogrel and
moking. Specifically, analyses comparing smokers and non-
mokers that include predominantly light smokers might
ail to show a significant interaction.
It also is possible that smoking is associated with the
agnitude of clinical benefit of clopidogrel for reasons in
ddition to or other than altering clopidogrel biotransfor-
ation into an active metabolite. There are data that
moking is associated with platelet activation in vivo and ex
ivo (21–24). Thus, if they had more active platelets,
mokers might stand to gain greater benefit from more
ntensive antiplatelet therapy. However, we should note that
e did not see any significant difference in angiographic or
linical events in the placebo arm across smoking categories.
tudy limitations. First, this was a post hoc analysis of a
ompleted clinical trial. However, as we have noted in the
receding text, there are multiple pharmacologic studies
hat formed the basis for our hypothesis. Second, due to the
ample handling and assay complexity necessary for platelet
ggregation studies, these evaluations could not be imple-
ented in CLARITY–TIMI 28, a large multinational
linical trial. Thus, although our findings are consistent with
ata from recent platelet aggregation studies, within our
ataset the mechanistic link between smoking and the
fficacy of clopidogrel remains speculative. Third, the sub-
roup of those who smoked 1 to 9 cigarettes/day was
elatively small; hence the CIs surrounding the effect esti-
ates for clopidogrel in this group were wide. Four,
moking status was, of course, not randomized. For that
eason, we did not examine the association between smok-
ng status and outcomes but rather the effect of randomly
llocated clopidogrel therapy on outcomes within smoking
ubgroups. Although the effect modification of smoking on
lopidogrel efficacy persisted after careful multivariable ad-
ustment, we cannot exclude residual confounding due to
nmeasured or unknown variables. Five, we did not adjust
or medications that have been associated with altered
lopidogrel pharmacology such as statins metabolized by
1YP3A4 or proton pump inhibitors (25,26). Use of proton
ump inhibitors was not collected on the case report form.
se of statins was collected, but administration of
YP3A4-metabolized statins was not imbalanced across
moking categories. Furthermore, data from 3 randomized
rials of clopidogrel (including ours, data not shown) have
hown no clinical effect modification by statin therapy
27,28).
onclusion
igarette smoking seems to positively modify the beneficial
ffect of clopidogrel on both angiographic and clinical
utcomes. These data highlight the contribution of envi-
onmental factors to the interpatient variability in response
o clopidogrel.
eprint requests and correspondence: Dr. Marc S. Sabatine,
ardiovascular Division, Brigham and Women’s Hospital, 75
rancis Street, Boston, Massachusetts 02115. E-mail: msabatine@
artners.org.
EFERENCES
1. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic
Events Trial Investigators. Effects of clopidogrel in addition to aspirin
in patients with acute coronary syndromes without ST-segment
elevation. N Engl J Med 2001;345:494–502.
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel
to aspirin and fibrinolytic therapy for myocardial infarction with
ST-segment elevation. N Engl J Med 2005;352:1179–89.
3. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for
coronary stenting: response variability, drug resistance, and the effect of
pretreatment platelet reactivity. Circulation 2003;107:2908–13.
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is
associated with increased risk of recurrent atherothrombotic events in
patients with acute myocardial infarction. Circulation 2004;109:
3171–5.
5. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree
of peri-interventional platelet inhibition after loading with clopidogrel
on early clinical outcome of elective coronary stent placement. J Am
Coll Cardiol 2006;48:1742–50.
6. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients
and recurrent events post-stenting: results of the PREPARE POST-
STENTING Study. J Am Coll Cardiol 2005;46:1820–6.
7. Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet
reactivity in patients with stent thrombosis: results of the CREST
Study. J Am Coll Cardiol 2005;46:1827–32.
8. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of
clopidogrel is due to a metabolic activation by the hepatic cytochrome
P450-1A. Thromb Haemost 1994;72:313–7.
9. O’Donoghue M, Wiviott SD. Clopidogrel response variability and
future therapies: clopidogrel: does one size fit all? Circulation 2006;
114:e600–6.
0. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in
individual responsiveness to clopidogrel: clinical implications, manage-
ment, and future perspectives. J Am Coll Cardiol 2007;49:1505–16.
1. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymor-
phisms and response to clopidogrel. N Engl J Med 2009;360:354–62.
2. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of
response to clopidogrel and cardiovascular events. N Engl J Med
2009;360:363–75.
3. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymor-
phism in young patients treated with clopidogrel after myocardial
infarction: a cohort study. Lancet 2009;373:309–17.4. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An
update. Clin Pharmacokinet 1999;36:425–38.
11
1
1
1
2
2
2
2
2
2
2
2
2
1278 Desai et al. JACC Vol. 53, No. 15, 2009
Smoking and Clinical Benefit of Clopidogrel April 14, 2009:1273–85. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette
smoking with enhanced platelet inhibition by clopidogrel. J Am Coll
Cardiol 2008;52:531–3.
6. Sabatine MS, McCabe CH, Gibson CM, Cannon CP. Design and
rationale of Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–
Thrombolysis in Myocardial Infarction (TIMI) 28 trial. Am Heart J 2005;
149:227–33.
7. Vistisen K, Loft S, Poulsen HE. Cytochrome P450 IA2 activity in
man measured by caffeine metabolism: effect of smoking, broccoli and
exercise. Adv Exp Med Biol 1991;283:407–11.
8. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on
cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178–84.
9. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel
is associated with cardiovascular outcome after coronary stent implan-
tation. Eur Heart J 2006;27:2420–5.
0. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance
of post-clopidogrel platelet reactivity assessed by a point-of-care assay
on thrombotic events after drug-eluting stent implantation. Eur
Heart J 2008;29:992–1000.
1. Levine PH. An acute effect of cigarette smoking on platelet function.
A possible link between smoking and arterial thrombosis. Circulation
1973;48:619–23.
2. Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence
of a chronic abnormality in platelet and vascular function in healthy
individuals who smoke cigarettes. Circulation 1987;76:6–14. K3. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking
acutely increases platelet thrombus formation in patients with coronary
artery disease taking aspirin. Circulation 1995;92:2432–6.
4. Harding SA, Sarma J, Josephs DH, et al. Upregulation of the
CD40/CD40 ligand dyad and platelet-monocyte aggregation in ciga-
rette smokers. Circulation 2004;109:1926–9.
5. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the
ability of clopidogrel to inhibit platelet aggregation: a new drug-drug
interaction. Circulation 2003;107:32–7.
6. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the
antiplatelet action of clopidogrel associated with aspirin: the random-
ized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
J Am Coll Cardiol 2008;51:256–60.
7. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-
atorvastatin clinical interaction from secondary analysis of a random-
ized, placebo-controlled clopidogrel trial. Circulation 2003;108:
921–4.
8. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a
clopidogrel-statin interaction in the CHARISMA trial. J Am Coll
Cardiol 2007;50:291–5.ey Words: clopidogrel y cytochrome P450 y smoking.
